A systematic review on SARS-CoV-2 remission: an emerging challenge for its management, treatment, immunization strategies, and post-treatment guidelines

R. Joshi, R. Singla, A. Mishra, M. Kumar, R. S. Singh, A. Singh, S. Bansal, A. R. Sharma, P. Sarma, A. Prakash and B. Medhi

Department of Pharmacology, Post Graduate Institute of Medical Education and Research, Chandigarh, India

Abstract

The COVID-19 disease caused by severe acute respiratory syndrome coronavirus -2 (SARS-CoV-2) has posed as a major health concern for people all across the globe. Along with the increasing confirmed patients being readmitted with complaints for fever, cough, cold, the effective monitoring of 'relapse' of the SARS-CoV-2 virus in the previously discharged patients have become the next area of focus. However, availability of limited data on reactivation of SARS-CoV-2 makes the disease prognosis as well as the effective control of re-infection an immense challenge. Prompted by these challenges, we assessed the possibility of re-infection in discharged patients and the risk of the transmission, proficiency of RT-PCR results and approximate period required for the quarantine, and the real challenges for the development of vaccine. In the present review, the published literature on all the possible cases of re-infection from February to July were reported, thereby selected 142 studies from a hub of overall 669 studies after full text screening. The incomplete virus clearance, poor sensitivity of the present diagnostic testing, emergence of mutant strains, insufficient mucus collection from the throat swab etc., are some of the possible causes of re-infection. The new protocols for management of COVID-19 discharged patients should be revised in the guidelines.

© 2022 Published by Elsevier Ltd.

Keywords: COVID-19, mutant strains, re-activation, re-emission, re-infection, relapse

Original Submission: 27 January 2021; Revised Submission: 12 May 2021; Accepted: 4 January 2022
Article published online: 7 January 2022

Introduction

The infection of SARS-CoV-2 has made the whole world feeble. Population of many countries got infected by this virus, which was claimed to be originated from Wuhan, China. All the scientists over the globe are engaged in researching the best treatment options and immunization strategies against the SARS-CoV-2 infection. Although a tremendous understanding of the virus, its types, have been done in the last five months but still many questions related to its immunity, mutations, relapse, and vaccination need to be explored. The fate of infection of this virus is still a mystery for scientists.

On one side various antiviral drugs, steroids, monoclonal antibodies, anti-microbials, convalescent plasma therapy etc., had been tried for its treatment, on the other side numerous vaccines have also been developed to combat this COVID-19 pandemic [1,2]. In spite of all these concepts, the incidence of relapse of COVID-19 patients has produced another challenge for the treating physicians as well as the researcher scientists and policymaker organizations all over the world. The conception of immunity to coronaviruses is not yet clear. However, the immunity to common cold viruses is not long-lasting but immunity to the previous outbreaks of coronaviruses like SARS-CoV in 2012 has been found to be long lasting but SARS-CoV-2 is not comprehensive [3,4]. The reports of re-infection or remission of SARS-CoV-2 infection are rising day by day from the last few months. The relapse cases were very
few in the month of March 2020 but had been increased suddenly till the second week of July, 2020. The published reports of re-infection cases from all over the globe were collected and summarized to find out the trend of re-infection. Moreover, the time of reoccurrence of the infection has also found to be unpredictable. Although a number of reasons for re-infection were discussed in few reports however, the actual cause of re-infection is not clear. In this review, the different reported cases are critically analyzed to accomplish the exact cause and treatment strategies to control the cases of re-infection. This would help in monitoring the COVID-19 patients for re-infection and to decide the quarantine or isolation period for the infected patients. The risk of spread of further infection from these relapse cases has also been discussed.

Objectives of this systematic review

- To evaluate the possibility of re-infection of COVID-19 in recovered/discharged patients and the risk of transmission of infection from re-infected patients
- To determine the certainty of the number of negative tests done on the COVID-19 patients to declare them safe or discharged proficiency
- To re-evaluate the proficiency of the results of RT-PCR to decide the chances of re-infection or remission of the disease
- To decide the approximate quarantine period required for the COVID-19 patients after its first discharge

Materials and methods

Search strategy and selection criteria

The published literature for the present review was obtained by searching the articles published from Feb to 20 July, 2020. This literature search was conducted on 1st April, 2020, using databases like PubMed, Science Direct, Google Scholar, Google), with the search terms: [‘COVID-19’ OR ‘SARS-CoV-2’ OR ‘SARS-CoV’ OR ‘Coronavirus’] AND [‘Reinfection’ OR ‘Reactivation’ OR ‘Relapse’ OR ‘Herd immunity’]. The list of the selected articles was finalized based on relevance to the topics covered in this review with no limitations on the language barriers.

This systematic review was designed to be effective enough to curtail the lacunae of the sufficient evidence of re-infection of the COVID-19 patients. Thus, we conducted a systematic review of studies on COVID-19 that included information on patients, which were re-infected with the SARS-CoV-2 infection. The present systematic review aimed to evaluate the association between the re-infection of COVID-19 and its outcomes incorporating the disease severity, duration of the latent period of re-infection, and management of the re-infection.

Inclusion criteria: Studies mentioning about the cases of relapse of COVID-19 patients were included. Peer reviewed original articles and review articles related to relapse and re-infection of SARS-CoV-2 were also included.

Exclusion criteria: Articles that have not discussed about the cases and reasons of re-infection or relapse of the SARS-CoV-2 virus were excluded. Moreover, articles in pre-print, which were not peer reviewed were also excluded.

After a rigorous search, we retrieved a total of 669 studies, of which 214 were found to be relevant to the topic after full text screening. A total of 142 studies were included after excluding the repeated studies and 14 studies of re-infection were discussed in detail (Fig. 1).

Maximum studies were from six countries namely, China, South Korea, Japan, Indonesia, Italy, and India. The study population included the patients with COVID-19, and the sample size ranged from a single case report to 447 patients. The study design involved retrospective methodology and the timeframe of the studies comprised the initial six months of the COVID-19 pandemic. The summary of all the included studies has been discussed in Table 1.

Results and discussion

The reasons for relapse of COVID-19 infection can be explained by many theories, that is, re-infection, reactivation of SARS-CoV-2, emergence of mutant strains, varied virus replication period, faults in testing results (false negatives). Some of the experimental studies have proven to be against the theory of re-infection. The monkeys when re-infected with the virus did not show the positive tests for the presence of a virus [5,6]. On the other hand, the results of another researcher from Fudan University, Shanghai, also reported low levels of antibodies in patients after COVID-19 infection. The following possible reasons for the relapse of COVID-19 have also been explained in Fig. 2.

To evaluate the possibility of re-infection of COVID-19 in recovered/discharged patients and the risk of transmission of infection from re-infected patient

The peer review survey regarding the re-infection studies, out of 142 studies only 14 studies had reported the relevant clinical cases of reinfection. Only 2–3 studies have done the long term follow up of the COVID-19 patients. The chances of re-infection in the reported studies varied from 2% to 31% [7–9]. The findings from the investigation and analysis of retrospective cases by the Korea Centre for Disease Control and
Prevention (KCDC), 790 contacts of the 285 re-positive cases were evaluated and no case of transmission of the virus from re-positive cases to their direct contacts was reported. Although the sample size of these studies was very less, thus it is difficult to conclude the possibility of relapse of COVID-19 infection [10]. In children, it was reported to be 50% in only one study of 15 patients [11].

Another cause of re-infection may be due to the induction of antibody-dependent enhancement of infection due to the presence of anti-S non-neutralizing or sub-neutralizing antibodies. So, the production of low levels of antibodies in a patient may lead to higher chances of re-infection with exacerbation of the disease.

Emergence of new strain of SARS-CoV-2: Emergence of novel coronavirus variants/strains can also cause re-infection. These variants used to escape the immune system and can cause reinfection in patients already recovered from Covid-19. The incidence of cases of new strain of SARS-CoV-2 originated from UK also leads to another challenge for the management of COVID-19. In the UK, there has been a rapid increase in COVID-19 cases in South East England, leading to enhanced epidemiological and virological investigations. Analysis of viral genome sequence data identified that a large proportion of cases belonged to a new single phylogenetic cluster. This strain is re-infecting the people already infected with SARS-CoV-2 in many countries. This variant strain is up to 70% more transmissible [12]. In India, the incidence of re-infection was reported with the new strain, that is, N440K in health care workers [13]. Thus, the emergence of new mutant strains could be among the various contributing reasons to re-infection.

To re-evaluate the proficiency of the results of RT-PCR to decide the chances of re-infection or remission of the disease

The problem of virus tests giving false negative results also interferes with the discharge criteria. The factors like procedure and time of sampling, transportation, and storage temperature, quality of testing kits result in false-negative tests. The location of virus replication inside the body may be causing hurdles in sampling like lower lungs, intestines, etc. Moreover, the presence of the residuals of viral RNAs can also give positive results. The dead virus or the viral gene fragments without actual viral replication also gave false-negative results [14]. Thus, relapse cases may be due to technical limits of PCR testing.

A large proportion of the discharged patients still carry virus and can act as asymptomatic virus carriers as they may carry...
| Country/study design | Patients (number/age/gender) | Latency period of re-infection | Symptoms on SARS-CoV-2 infection/reinfection | Findings | Inference |
|----------------------|-----------------------------|-------------------------------|---------------------------------------------|----------|-----------|
| Wuhan City, China/case presentation [21] | 01 (58-year-old woman) | 22 days | Fever, cough, white sticky sputum, chest pain, fatigue, dry mouth/no symptoms | Incomplete virus clearance, poor test sensitivity, insufficient virus collection from throat swabs | To add anal/stool test as diagnostic criteria along with throat swab test. To perform IgM and IgG antibody coronavirus test to avoid false negative and false positives. |
| Wenzhou, China/case series [7] | n = 20 (23–57 years) | 7 days | Fever and cough/no symptom | RNA positivity is less likely to be due to re-infection | Self-isolation protocols and extended follow up needed for the recovered COVID-19 patients. New protocols need to be applied to monitor discharged patients. Repeated sampling from different organs should be preferred. |
| Korea/report [10] | 447 (14.3 years) | 14.3 average | 44.7% had cough and sore throat | No evidence of infectivity of the re-positive cases | Sufficient sampling should be done. |
| Japan/newspaper report [22] | 01 (40-year-old woman) | 2 weeks | Sore throat and chest pain/sore throat and chest pain | Insufficient mucus from the swab tests | Insufficient virus from the swab tests Presence in dormant virus in discharged patients. |
| Indonesia/newspaper report [23] | 01 (25-year-old man) | 1 week | No symptom/anxiety and stress | Presence in dormant virus in discharged patients | |
| India/newspaper report [24] | 01 | 1 week | No symptom/follow up after quarantine | | |
| China/letter to editor [25] | 07 patients | 7–11 days | 4 = asymptomatic 3 = fever, cough, malaise/no symptoms | The discharge criteria of two repetitive negative RT-PCR tests not reliable | The necessity of adding RT-PCR testing of rectal swab specimens to the criteria for discharged COVID-19 patients. Close monitoring of the vulnerable patient population on the outpatient basis even after they overcome the infection. |
| South Korea/letter to editor [16] | 02 (81 and 77 year old woman) | 2–3 weeks | Cough and fever/dyspnea, fever, and confusion | Reactivation of the virus can be assumed in the present scenario | Therapy to be decided based on: Host factors: age, sex, type of disease. Viral factors: baseline SARS-COV2 workload, variable genotype Need to understand relationship of chance of viral transmission with patient viral load, determine whether the viral nucleic acid positivity in the re-positive cases is due to active or residual virus. |
| Wuhan, China/observational study [9] | 9% (5 out of 55) (Age- 27–42 years) | 9% (5 out of 55) (Age- 27–42 years) | Fever and cough/fever, cough, sore throat, and fatigue | Reactivation of the virus | |
| Yiwu, China/research article [13] | 31% (4/13) | 4 weeks | fever, cough, fatigue, muscle soreness, and sore throat | False negative test, Re-exposure to the virus, fecal-oral route may be another route for the SARS-CoV2 infection | |
| Italy/Letter to editor [20] | 01 (48-year-old man) | 1 month | fever, cough, shortness of breath, hypoxemia/chest pain | Reactivation of the virus, lgG antibodies are not completely protective | |
| Ningbo, China/retrospective study [27] | 17 | 4 days | chest pain, stuffness, nasal congestion, fatigue and diarrhea (other symptoms)/ fever cough | Possibly relapse, recurrent lessons in chest CT scans of the re-positive case, CD3-CD56 + NK cells levels higher in the relapse | |
| Guangdong, China/letter to editor [26] | 07 | 2–3 weeks | Fever, cough/out of 7, 2 report fever and one itchy throat | Shorter stay time and milder symptoms on re-infection Some patients have positive anal swabs while negative throat swab, false negative results during discharge | |
| Shandong, China/case series [29] | 07 | 2 weeks | 40% fever, 20 % cough, and 10% head phlegm/6-no symptom and 1-fever, cough, nausea, vomiting, diarrhea | Re-positive patients positive for SARS-COV-2 virus RNA in fecal specimens but negative for respiratory tract specimens | |
the low level of virus, which is not detected by the throat swabs. Thus, new suggestions for strengthening the discharge criteria as well as the new testing procedures for testing the COVID-19 patients have been proposed. For example: Li et al. emphasized the inclusion of a negative fecal virus nucleic acid testing in the discharge criteria of the COVID-19 patients. Also, examination of the discharged patients for the changes in the viral nucleic acid should be included [15].

Moreover, FDA has granted emergency use authorization for tests that identify antibodies, that is, IgG and IgM, against SARS-CoV-2 in serum or plasma. It has been found that serologic screening can be an important tool to understand population immunity and distinguish individuals who are at lower risk for re-infection. In some individuals, viral RNA can be detected from the respiratory tract months after the initial infection. Detectable viral RNA, however, does not always indicate the presence of infectious virus, and there appears to be a threshold of viral RNA level below which infectiousness is unlikely [16].

Another cause may be the variation in the clearance of the virus in co-morbid conditions like hypertension, diabetes, etc. Chest congestion in critically ill and elderly patients might also lead to delay in virus clearance [17]. In Shenzhen, 14.5% (38/262) of the patients were again found to be positive after discharge from hospitals without having any history of contact with positive patients. These studies are questioning the importance of herd immunity as well as the individual variations in the immunity against this virus [18].

To decide the approximate quarantine period required for the COVID-19 patients after their first discharge

The coronavirus replication is seething for an unusual long time and can also cause late reactivation. The length of virus detection also varied from person to person. It has been found that some patients showed positive RT-PCR tests after 1–2 weeks of discharge from the hospital after their first COVID-19 infection [19]. These patients may remain as virus carriers for a long time after their discharge. One of the major issues discussed by most of the experts as the possible cause of re-infection may be the insufficient quarantine period for the people before discharge. Thus, the positive tests after discharge do not always interpret the re-infection. As mentioned by Loconsole et al., essential domiciliary quarantine period of 14 days should be made mandatory for all the hospital discharged COVID-19 patients as the average time of the presence of virus in an infected patient fluctuates and the risk of reactivation of virus in previously discharged patients poses a major public threat of transmission. Some other reasons for increasing the quarantine period include the chances of false negative results at the molecular tests, which may be due to the lack of sensitivity of the instrument or the tissue collection errors. Also, after increasing reports of the reoccurrence of the virus, quarantine period also increased to 14 days after recovery [20]. However, according to the reports of the Korea Centre for Disease Control and Prevention, the previous criteria that included a 14 day of self-isolation for the COVID-19 patients after discharge as a step towards
management of the confirmed and re-positive cases was considered to be non-essential from 19 May, 2020 after an extensive epidemiological study on the re-positive cases [10].

Conclusion

Various reports all over the globe came with re-infection after discharge from the hospitals. The latent period of re-infection varied from 7–28 days. It has been found that the symptoms after re-infection in most of the cases were not severe and did not perpetuate to death. In these re-infected patients, although the RT-PCR results were positive but anti-viral therapy was not required. However, the risk of transmission of the virus from these re-infected patients is low but there is no firm evidence that these patients can not transmit the infection further. Thus, the risk of relapse of COVID-19 infection should not be overlooked and larger studies should be conducted to monitor the patients for a long time after their discharge from the hospitals. The guidelines regarding the quarantine period after the discharge of the patients and the frequency of negative RT-PCR results should be updated. There is also an urgent need for the diagnostic tests, which can predict the chances of re-infection with SARS-CoV-2. Further, the advanced strategies about diagnostic criteria, treatment as well as management of this pandemic and its immunity should be made on the evidence-based outcomes.

Transparency declaration

Nothing to declare.

Funding source

No funding.

References

[1] Prajapat M, Sarma P, Shekhar N, Avti P, Sinha S, Kaur H, et al. Drug targets for corona virus: a systematic review. Indian J Pharmacol 2020;52(1):56–65.
[2] Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA 2020;324(5):1–11.
[3] Zhao J, Zhao J. Mangalam AK, Channappanavar R, Fett C, Meyerholz DK, et al. Airway memory CD4(+) T cells mediate protective immunity against emerging respiratory coronaviruses. Immunity 2016;44(6):1379–91.
[4] Raoul D, Zumla A, Locatelli F, Ippolito G, Kroemer G. Coronavirus infections: epidemiological, clinical and immunological features and hypotheses. Cell Stress 2020;4(4):66–75.
[5] Ota M. Will we see protection or reinfection in COVID-19? Nat Rev Immunol 2020;20(6):351.
[6] Singla R, Mishra A, Joshi R, Jha S, Sharma AR, Upadhyay S, et al. Human Animal interface of SARS-CoV-2 (COVID-19) transmission: a critical appraisal of scientific evidence. Vet Res Commun 2020;44:119–30.
[7] Zheng KL, Wang XB, Jin XH, Liu WY, Gao F, Chen YP, et al. A case series of recurrent viral RNA positivity in recovered COVID-19 Chinese patients. J Gen Intern Med 2020;35(7):2205–6.
[8] Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, et al. Clinical characteristics of severe acute respiratory syndrome coronavirus 2 reactivation. J Infect 2020;80(5):e14–7.
[9] Li J, Zhang C, Wu Z, Wang G, Zhao H. The Mechanism and Clinical Outcome of patients with Corona Virus Disease 2019 Whose Nucleic Acid Test has changed from negative to positive, and the therapeutic efficacy of Favipiravir: a structured summary of a study protocol for a randomized controlled trial. Trials 2020;21:488.
[10] Korean Centre for disease control and prevention. Findings from investigation and analysis of Re-positive cases. 2020. [Accessed 24 June 2020].
[11] Zhao W, Wang Y, Tang Y, Zhao W, Fan Y, Liu G, et al. Characteristics of children with reactivation of SARS-CoV-2 infection after hospital discharge. Clin Pediatr (Phila) 2020;59(9–10):929–32.
[12] Guo G, Ye L, Pan K, Chen Y, Xing D, Yan K, et al. New insights of emerging SARS-CoV-2: epidemiology, etiology, clinical features, clinical treatment, and prevention. Front Cell Dev Biol 2020;8:410.
[13] Rani PR, Imran M, Lakshmi JV, Jolly B, Jain A, Suresh K, et al. Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape. J Med Virol 2021 Apr 5. https://doi.org/10.1002/jmv.26997.
[14] Kang H, Wang Y, Tong Z, Liu X. Retest positive for SARS-CoV-2 RNA of “recovered” patients with COVID-19: persistence, sampling issues, or re-infection? J Med Virol 2020;1–3.
[15] Li Y, Hu Y, Yu Y, Zhang X, Li B, Wu J, et al. Positive result of Sars-CoV-2 in faeces and sputum from discharged patients with COVID-19 in Yiwu, China. J Med Virol 2020;92(10):1938–47.
[16] Abbasi J. The promise and peril of antibody testing for COVID-19. JAMA 2020;323(19):1881–3.
[17] Hu X, Xing Y, Jia J, Niu W, Liang J, Zhao D, et al. Factors associated with negative conversion of viral RNA in patients hospitalized with COVID-19. Sci Total Environ 2020;728:138812.
[18] Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID-19 in a designated infectious diseases hospital outside Hubei Province, China. Allergy 2020;1–11. 00.
[19] Gao Z, Xu Y, Guo Y, Xu D, Zhang L, Wang X, et al. A systematic review of re-detectable positive virus nucleic acid among COVID-19 patients in recovery phase. Infect Genet Evol 2020;85:104494.
[20] Loconsole D, Passerini F, Palmieri VO, Centrone F, Sallustio A, Pugliese S, et al. Recurrence of COVID-19 after hospital recovery: a case report from Italy. Infection 2020;48(6):965–7.
[21] Luo A. Positive SARS-CoV-2 test in a woman with COVID-19 at 22 days after hospital discharge: a case report. J Traditional Chin Med Sci 2020;7(4):13–7.
[22] Japanese woman reinfected with coronavirus weeks after initial recovery, East Asia News & Top Stories - The Straits Times. 2020. Published Feb 27, 2020, 11:32 am sgt updated Feb 28, 2020, 10:23 pm. [Accessed 25 June 2020].
[23] ‘Reinfected’ North Sumatra COVID-19 patient ‘feels fine, but stressed’ - National - The Jakarta Post. https://www.thejakartapost.com/news/
2020/05/11/reinfected-north-sumatra-covid-19-patient-feels-fine-but-stressed.html.

[24] https://www.indiatoday.in/india/story/himachal-covid-19-patient-from-kangra-tests-positive-after-recovering-from-infection-1668783-2020-04-19. [Accessed 20 June 2020].

[25] Zhang B, Liu S, Dong Y, Zhang L, Zhong Q, Zou Y, et al. Positive rectal swabs in young patients recovered from coronavirus disease 2019 (COVID-19). J Infect 2020;81(2):e49–52.

[26] Ravioli S, Ochsner H, Lindner G. Reactivation of COVID-19 pneumonia: a report of two cases. J Infect 2020;81(2):e72–3.

[27] Zhu H, Fu L, Jin Y, Shao J, Zhang S, Zheng N, et al. Clinical features of COVID-19 convalescent patients with re-positive nucleic acid detection. J Clin Lab Anal 2020;34(7):e23392.

[28] Peng J, Wang M, Zhang G, Lu E. Seven discharged patients turning positive again for SARS-CoV-2 on quantitative RT-PCR. Am J Infect Control 2020;48(6):725–6.

[29] Du W, Yu J, Liu X, Chen H, Lin L, Li Q. Persistence of SARS-CoV-2 virus RNA in feces: a case series of children. J Infect Publ Health 2020;13(7):926–31.